Polycystic Kidney Disease – Special Topics – Special Topic: Quantitative Physician Insights – US, EU5, Japan, China
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the early stages, the disease is often asymptomatic and detectable only through diagnostic imaging of the kidney to reveal cysts. The launch of Otsuka’s Jynarque / Jinarc / Samsca (tolvaptan) introduced the first disease-specific therapy for ADPKD. However, many opportunities remain for emerging ADPKD therapies owing to limitations of tolvaptan. For example, tolvaptan is not a disease-modifying therapy; its efficacy is considered moderate by thought-leaders interviewed; it is indicated only in adults who have rapidly progressing, or are at risk for, rapidly progressing ADPKD; and it is commonly associated with aquaretic adverse events. We examine how tolvaptan’s launch has impacted ADPKD patient treatment and the challenges / opportunities that emerging therapies will face entering this market.
QUESTIONS ANSWERED
- How are patients diagnosed, categorized, and monitored? Is patient risk categorized? How frequently are patients monitored?
- Which patients are prescribed tolvaptan? For which attributes do physicians think tolvaptan performs best / worst? How has tolvaptan’s launch affected the ADPKD treatment algorithm?
- What are the greatest unmet needs in the treatment of ADPKD patients?
- Based on four hypothetical drug product profiles, which attributes are most important to physicians’ prescribing decisions?
Geographies
- United States, EU5 (France, Germany, Italy, Spain, United Kingdom), Japan, China
Primary research
- Survey of 350 nephrologists: 50 China, 150 EU5 (30 each in France, Germany, Italy, Spain, United Kingdom), 100 United States, 50 Japan
Key drugs covered
- Tolvaptan, emerging therapies
Key insights provided
- Analysis of drug development opportunities
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices
- Rationale for changes in treatment approach
- Physician-reported recent / anticipated changes in brand usage or treatment approach
- Physician perceptions of unmet needs in the indication and related indications
PRODUCT DESCRIPTION
Special Topic: Quantitative Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
